• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

ENBREL Indication Expanded

The FDA approved an expanded indication for Enbrel (etanercept) to inhibit the structural damage of active arthritis in patients with psoriatic arthritis, reported Amgen Inc. and Wyeth Pharmaceuticals.

Related Videos
Related Content
Pediatric Patients with Atopic Dermatitis Have Lower SCH and Higher TEWL, Compared to Those Without
January 22nd 2025

Pediatric Patients with Atopic Dermatitis Have Lower SCH and Higher TEWL, Compared to Those Without

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
August 1st 2023

The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis

Pediatric Melanoma in Review: Providing Considerations for Dermatologists
November 22nd 2024

Pediatric Melanoma in Review: Providing Considerations for Dermatologists

The Cutaneous Connection
August 5th 2021

The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD
November 4th 2024

Off-Treatment Remission Achieved with Dupilumab for Pediatric AD

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds
October 24th 2024

Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds

© 2025 MJH Life Sciences

All rights reserved.